Expression of CD200 on AML blasts directly suppresses memory T-cell function

Leukemia

Volumn 26, Issue 9, 2012, Pages 2148-2151

  Coles, S J ^a   Hills, R K ^a   Wang, E C Y ^a   Burnett, A K ^a   Man, S ^a   Darley, R L ^a   Tonks, A ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; IONOMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LETTER; LEUKEMIA CELL; PRIORITY JOURNAL; TUMOR IMMUNITY;

EID: 84865860666     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.77     Document Type: Letter

References (17)

1. Liepert A, Grabrucker C, Kremser A, Dreyssig J, Ansprenger C, Freudenreich M et al. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. Cell Immunol 2010; 265: 23-30.
2. Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud O. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol 2010; 11: 38.
3. Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z et al. Elevated frequencies of CD4( +)CD25( +)CD127(lo) regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 2010; 129: 1373-1381.
4. Yoshida M, Akiyama N, Fujita H, Miura K, Miyatake J, Handa H et al. Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int J Hematol 2011; 93: 66-73.
5. Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007; 21: 566-568.
6. Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011; 117: 6267-6276.
7. Guo H, Qiao Z, Zhu L, Wang H, Su L, Lu Y et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients following nonmyeloablative allogeneic stem cell transplantation. Am J Hematol 2004; 75: 78-83. (Pubitemid 38160595)
8. McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 2006; 103: 1041-1046. (Pubitemid 43212218)
9. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 2008; 57: 987-996.
10. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8: 247-258. (Pubitemid 351432801)
11. Smith KL, Tristram A, Gallagher KM, Fiander AN, Man S. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. Int Immunol 2005; 17: 167-176. (Pubitemid 40246581)
12. Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 2008; 9: 1074-1083.
13. Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 2001; 102: 173-179. (Pubitemid 32217509)
14. Gallagher KM, Man S. Identification of HLA-DR1-and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4 + T cells from healthy young women. J Gen Virol 2007; 88: 1470-1478. (Pubitemid 46723228)
15. Coles SJ, Wang EC, Man S, Hills RK, Burnett AK, Tonks A et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 2011; 25: 792-799.
16. Wang L, Liu JQ, Talebian F, El-Omrani HY, Khattabi M, Yu L et al. Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy. Eur J Immunol 2010; 40: 2569-2579.
17. Coles SJ, Hills RK, Wang ECY, Burnett AK, Man S, Darley RL et al. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3 + regulatory T-cells. Leukemia 2012; 26: 2148-2151.